Persistence of mRNA indicative of Plasmodium falciparum ring-stage parasites 42 days after artemisinin and non-artemisinin combination therapy in naturally infected Malians

Table 4 Prevalence and density of ring-stage parasites by recurrent infection type

Infection Type	Prevalence, n (%)	Ring-stage parasite density (per μL), median [IQR]
Infection Type	Prevalence, n (%)	Day 7	p-value	Day 14	p-value	Day 28	p-value
Treatment success	63 (86)	0 [0, 0.07]	Ref	0 [0, 0]	Ref	0 [0, 0]	Ref
Recurrent	10 (14)	0 [0, 0]	0.99	0.08 [0, 0.4]	0.011	0 [0, 0.3]	0.068
Recrudescent	4 (5)	0 [0, 6.5]	0.57	5.6 [0,11.2]	0.12	14.2 [0, 28.4]	0.029
Re-infection	4 (5)	0 [0, 0.4]	0.92	0.08 [0, 0.2]	0.085	0 [0, 0]	0.61
Indeterminate	2 (3)	0 [0, 0]	0.40	0.3 [0, 0.7]	0.12	0.1 [0, 0.3]	0.041

To assess whether prior ring-stage parasite densities were associated with increased risk of recurrent infections, parasite densities for each column of recurrent infections excludes those that were detected before or on that day of follow-up. For example, ring-stage parasite densities for recrudescent infections on day 14 excludes recrudescent infections that occurred on day 7 (n = 1) and day 14 (n = 1)
p-values were computed using the Mann–Whitney test. Comparisons are between recurrent infection categories to reference category (Treatment Success)

ISSN: 1475-2875